ClinicalTrials.gg
RecruitingNCT06697600UR-GOAL RCTUpdated Jul 6, 2026

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

An interventional study of UR-GOAL in Oncology, Myeloid Leukemia, Acute and Cancer, sponsored by University of Rochester. Recruiting at 4 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Primary conditionLeukemia, Myeloid, AcuteRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. The study's listed conditions name Leukemia, Myeloid, Acute, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Rochester · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,020
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Leukemia, Myeloid, Acute by University of Rochester — 5 open to participants now, 5 under way, none of them phase 3. Leukemia, Myeloid, Acute · University of Rochester.

Planned enrollment
Largest of 12
1,020 · median 26
Started
2025
the only one that year
No phase
7 of 14
2 open now
Registered
12th of 14
by date

Among the 14 studies in Leukemia, Myeloid, Acute by University of Rochester, this one has the largest planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 7 with no phase, and was the 12th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

5 of the 14 studies in Leukemia, Myeloid, Acute by University of Rochester are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Leukemia, Myeloid, Acute by University of Rochester, or all of them as a file.
02

Study summary

This is a multicenter randomized controlled trial that assesses the efficacy of a decisional intervention [University of Rochester-Geriatric Oncology assessment for Acute myeloid Leukemia (UR-GOAL)] compared to an attention control.

Read the detailed description

This is a multicenter randomized controlled trial with four sites that assesses the efficacy of a decisional intervention [University of Rochester-Geriatric Oncology assessment for Acute myeloid Leukemia (UR-GOAL)] compared to an attention control. Subjects will be randomized 1:1 to either the intervention arm or the attention control arm. Compared to an attention control, UR-GOAL will improve patient distress, observed and patient-perceived shared decision making (SDM), and patient decisional conflict.

03

Conditions studied

  • Oncology
  • Myeloid Leukemia, Acute
  • Cancer

Browse trials for

Keywords

  • older adults
  • geriatric oncology
  • caregivers
04

In context

Leukemia, Myeloid, Acute Reclassified

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

This study's planned enrollment of 1,020 is above the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

University of Rochester is the lead sponsor of 729 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients

Inclusion criteria:

  • Age ≥60 years (from date of consent, confirmed on electronic medical records)
  • A new diagnosis of AML

    • Diagnosis can be based on the International Consensus Classification or World Health Organization
    • Myeloid sarcoma is allowed
    • AML with central nervous system involvement is allowed
  • Cancer-directed treatment has not started

    • Treatment to temporarily decrease white blood cells is acceptable; these may include hydroxyurea, leukapheresis, or cytarabine
    • Intrathecal chemotherapy is acceptable
  • The patient's oncologist has been or will be enrolled on the study
  • English or Spanish-speaking
  • Patients without a caregiver will still be eligible to participate in the study Exclusion criteria
  • A diagnosis of acute promyelocytic leukemia
  • Patients with psychiatric or cognitive conditions which the treating oncologist believes prohibits or compliance with study procedures
  • Prior cancer-directed treatment for AML

Caregivers

Inclusion criteria:

  • Selected by the patient when asked if there is a "family member, partner, friend or caregiver [age 18 or older] with whom you discuss or who can be helpful in healthrelated matters."
  • Caregiver may be paid/professional or informal caregiver
  • Able to provide informed consent
  • English or Spanish-speaking

Oncologists

Inclusion criteria:

  • Oncologists caring for patients with AML Exclusion criteria
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,020 participants (estimated)

Study arms

  • Experimental
    UR-GOAL Intervention

    Patients will view an AML video, complete the best-worst scaling, and be provided with a summary report consisting of their priorities; they will will be asked to review and discuss at upcoming clinical visits. Caregivers, if available, will view the same AML video and be provided with the same summary report. Oncologists will be provided with a summary report consisting of the patient's geriatric assessment, priorities, and perception of prognosis; they will be asked to review and discuss at upcoming clinical visits.

    Behavioral: UR-GOAL

  • No intervention
    Attention Control Arm

    Patients will view a nutritional video, complete a nutrition questionnaire, and will be provided with a nutrition handout and asked to review and discuss at upcoming clinical visits. Caregivers, if available, will view the nutritional video, and will be provided with a nutrition handout and asked to review and discuss at upcoming clinical visits. Oncologists will be provided with the patient's completed nutrition questionnaire and asked to review and discuss at upcoming clinical visits.

Interventions

  • BehavioralUR-GOAL

    Patients will view an AML video, complete the best/worst scaling, will be provided with a summary report, and will be asked to review and discuss at upcoming clinical visits. Caregivers, if available, will view an AML video, will be provided with a summary report, and will be asked to review. Oncologists will be provided with a summary report and will be asked to review and discuss at upcoming clinical visits.

07

What researchers measure

Primary outcomes

  1. Distress Thermometer Questionnaire at 1 month

    A self-report measure to capture distress and identify a list of sources of that distress. This is a 10-item scale, rated from 0-10 (0=no distress, 10=severe distress), with a possible total of 10; a higher score indicates greater distress.

    Time frame: 1 month

Secondary outcomes

  1. 9-item Shared Decision Making Questionnaire at 2 weeks

    9-item Shared Decision Making Questionnaire at 2 weeks

    Time frame: 2 weeks

  2. Decisional Conflict Scale Questionnaire at 2 weeks

    Decisional Conflict Scale Questionnaire at 2 weeks

    Time frame: 2 weeks

  3. Observed shared decision making

    OPTION5 instrument from audio-recorded treatment decision-making clinical visits

    Time frame: Day 0

08

Study locations

4 of 4 sites recruiting
09

References and documents

Publications

  • LoCastro M, Sanapala C, Wang Y, Jensen-Battaglia M, Wittink M, Norton S, Klepin HD, Richardson DR, Mendler JH, Liesveld J, Huselton E, O'Dwyer K, Cortes AM, Rodriguez C, Dale W, Loh KP. Patient-centered communication tool for older patients with acute myeloid leukemia, their caregivers, and oncologists: A single-arm pilot study. Cancer Med. 2023 Apr;12(7):8581-8593. doi: 10.1002/cam4.5547. Epub 2022 Dec 19. PubMed 36533397 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Oct 2029, 50 months after the start.

Of 132 non-industry interventional studies with no phase under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 128. This study's planned 50 months is close to that.

Counting every sponsor, half of 139 studies reached it within 47 months; a quarter within 25 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2024
First posted
Nov 20, 2024
StartActual
Jul 11, 2025
Primary completionEst.
Oct 1, 2029
CompletionEst.
Jun 1, 2030
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06697600
Responsible party
Kah Poh Loh (Associate Professor, Division of Hematology/Oncology, Department of Medicine, University of Rochester) — Principal investigator
First posted
Nov 20, 2024
Start date
Jul 11, 2025
Primary completion
Oct 1, 2029 (estimated)
Completion
Jun 1, 2030 (estimated)
Last update
Jul 6, 2026

Study contacts

Kah Poh Loh
Contact
Kahpoh_Loh@URMC.Rochester.edu
585-276-4353
Becky Gravenstede
Contact
becky_gravenstede@urmc.rochester.edu
585-727-4728

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion